Focus Partners Advisor Solutions LLC Acquires 14,716 Shares of Abbott Laboratories $ABT

Focus Partners Advisor Solutions LLC increased its holdings in shares of Abbott Laboratories (NYSE:ABT) by 470.5% in the fourth quarter, HoldingsChannel reports. The firm owned 17,844 shares of the healthcare product maker’s stock after buying an additional 14,716 shares during the period. Focus Partners Advisor Solutions LLC’s holdings in Abbott Laboratories were worth $2,236,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of ABT. MidAtlantic Capital Management Inc. bought a new stake in shares of Abbott Laboratories during the fourth quarter worth approximately $25,000. Harbor Capital Advisors Inc. bought a new stake in shares of Abbott Laboratories during the fourth quarter worth approximately $27,000. Bridge Generations Wealth Management LLC bought a new stake in shares of Abbott Laboratories during the third quarter worth approximately $33,000. Leonteq Securities AG bought a new stake in shares of Abbott Laboratories during the fourth quarter worth approximately $35,000. Finally, Board of the Pension Protection Fund bought a new stake in shares of Abbott Laboratories during the fourth quarter worth approximately $38,000. Institutional investors own 75.18% of the company’s stock.

Insider Activity at Abbott Laboratories

In other news, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction on Monday, April 27th. The stock was acquired at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the transaction, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Philip P. Boudreau acquired 2,200 shares of the stock in a transaction on Thursday, April 23rd. The shares were purchased at an average price of $91.50 per share, with a total value of $201,300.00. Following the completion of the transaction, the chief financial officer owned 2,200 shares of the company’s stock, valued at approximately $201,300. This represents a ? increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 0.46% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Bank of America reduced their price objective on Abbott Laboratories from $150.00 to $120.00 and set a “buy” rating for the company in a report on Friday, April 17th. The Goldman Sachs Group reduced their price objective on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a report on Wednesday, May 27th. Jefferies Financial Group reduced their price objective on Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a report on Friday, April 17th. Daiwa Securities Group cut Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price objective for the company. in a report on Wednesday, April 22nd. Finally, TD Cowen reduced their price objective on Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating for the company in a report on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $119.09.

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $89.15 on Thursday. The stock’s fifty day moving average price is $92.01 and its two-hundred day moving average price is $108.39. Abbott Laboratories has a one year low of $81.97 and a one year high of $139.06. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The firm has a market cap of $155.29 billion, a PE ratio of 24.97, a price-to-earnings-growth ratio of 1.52 and a beta of 0.63.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same period in the previous year, the business earned $1.09 earnings per share. The company’s revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, research analysts expect that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott continues to gain attention for its cancer diagnostics growth story, with the Exact Sciences acquisition expanding its diagnostics portfolio and supportive screening data improving the long-term outlook. Mounting Evidence Backs Abbott’s Cancer Diagnostics Growth Story
• Positive Sentiment: Abbott also received a boost from news that it secured CE Mark for its Libre Duo dual glucose-ketone sensing technology, a potential growth driver in diabetes care. Abbott (ABT) Secures CE Mark for World’s First Dual Glucose-Ketone Sensing Technology for Diabetes
• Neutral Sentiment: ABT is being highlighted as a trending stock across financial media, suggesting rising investor interest but not necessarily a clear catalyst by itself. Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Analyst commentary also noted Abbott as a blue-chip, defensive name for long-term portfolios, reinforcing its stability and dividend appeal rather than signaling a near-term earnings surprise. New Investors: 3 Rock-Solid Stocks to Build Your Portfolio Around
• Negative Sentiment: Despite the positive business updates, the stock has still been trading lower, reflecting broader selling pressure and investor caution after recent gains. Abbott (ABT) Dips More Than Broader Market: What You Should Know

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.